SCN10A encodes the Nav1.8 voltage-gated sodium channel, also known as NaV1.8 or SCN10A. This channel is a member of the Nav1 family of voltage-gated sodium channels (Nav1.1–Nav1.9) and is predominantly expressed in peripheral sensory neurons, particularly those involved in pain signaling. Nav1.8 is crucial for the generation and propagation of action potentials in nociceptive (pain-sensing) neurons and plays a lesser but significant role in cardiac electrical conduction[@waxman2020].
The channel's unique electrophysiological properties—including slow inactivation kinetics, tetrodotoxin resistance, and temperature-dependent activation—make it a critical player in pain transduction. SCN10A variants are associated with a spectrum of clinical conditions ranging from painful peripheral neuropathies to cardiac arrhythmias, making Nav1.8 an important therapeutic target for both pain management and cardiac disorders.
¶ Gene Structure and Organization
The human SCN10A gene spans approximately 31 kb on chromosome 3p21-p22 and encodes a large membrane protein. The gene structure reflects the complexity required for precise regulation of this ion channel.
| Feature |
Details |
| Chromosome |
3p21-p22 |
| Genomic Span |
~31 kb |
| Exons |
26 coding exons |
| Transcript Length |
~7.5 kb |
| Protein Length |
2016 amino acids |
| Molecular Weight |
~220 kDa |
Multiple SCN10A splice variants have been identified:
- Canonical Isoform: Full-length Nav1.8 (2016 aa)
- Alternative Exon 18 Variants: Generate channels with altered kinetics
- Truncated Variants: May have regulatory functions
- Neural vs. Cardiac Isoforms: Tissue-specific splicing patterns
¶ Protein Structure and Function
Nav1.8 is a large transmembrane protein that forms a functional sodium channel complex. Like other voltage-gated sodium channels, Nav1.8 consists of four homologous domains (I–IV), each containing six transmembrane segments (S1–S6).
graph TB
subgraph Nav1.8 Structure
A["Domain I"] --> A1["S1-S6"]
B["Domain II"] --> B1["S1-S6"]
C["Domain III"] --> C1["S1-S6"]
D["Domain IV"] --> D1["S1-S6"]
A1 --> A2["Voltage Sensor S4"]
B1 --> B2["Voltage Sensor S4"]
C1 --> C2["Voltage Sensor S4"]
D1 --> D2["Voltage Sensor S4"]
A1 --> A3["Pore Region S5-S6"]
B1 --> B3["Pore Region S5-S6"]
C1 --> C3["Pore Region S5-S6"]
D1 --> D3["Pore Region S5-S6"]
end
- Voltage Sensor Domain (S4): Contains positively charged residues that sense membrane potential changes
- Pore Domain (S5-S6): Forms the ion selectivity filter and gate
- Inactivation Gate: The III-IV linker contains the fast inactivation particle
- C-terminal Domain: Contains interaction sites for regulatory proteins
Nav1.8 exhibits several distinctive properties that differentiate it from other sodium channels:
| Property |
Nav1.8 |
Nav1.7 |
Nav1.5 |
| Activation Threshold |
High (~-30 mV) |
Low (~-55 mV) |
Moderate |
| Inactivation Rate |
Slow |
Fast |
Moderate |
| Tetrodotoxin Sensitivity |
TTX-R |
TTX-S |
TTX-R |
| Recovery from Inactivation |
Slow |
Fast |
Moderate |
| Temperature Sensitivity |
High |
Moderate |
Low |
- Slow Inactivation: Allows sustained sodium currents during repetitive firing, enabling high-frequency action potential generation in nociceptors
- TTX-R: Insensitive to tetrodotoxin, making Nav1.8 resistant to puffer fish toxin
- Temperature Sensitivity: Activates at warmth threshold (>40°C), directly linking temperature to pain signaling
- High Activation Threshold: Ensures activation only during strong noxious stimuli
¶ Tissue Distribution and Cell-Type Specificity
Nav1.8 is predominantly expressed in:
flowchart TB
A["SCN10A Expression"] --> B["Dorsal Root Ganglion"]
A --> C["Trigeminal Ganglion"]
A --> D["Nodose Ganglion"]
A --> E["Sympathetic Ganglia"]
B --> B1["Small-Diameter C-Fibers"]
B --> B2["Aδ-Fibers"]
B --> B3["Medium-Diameter Neurons"]
C --> C1["Trigeminal Pain Neurons"]
style B fill:#e3f2fd
style C fill:#e3f2fd
| Cell Type |
Expression Level |
Primary Function |
| Nociceptive C-fibers |
High |
Pain detection |
| Aδ-fiber neurons |
High |
Sharp pain, temperature |
| Thermoreceptors |
Moderate |
Temperature sensing |
| Sympathetic neurons |
Low-Moderate |
Autonomic regulation |
| Cardiac sensory neurons |
Low |
Cardiac nociception |
While primarily a neuronal channel, Nav1.8 has minor expression in the cardiac conduction system:
- Sinoatrial Node: Modulates pacemaker activity
- Atrioventricular Node: Affects conduction velocity
- His-Purkinje System: Contributes to ventricular conduction
- Minimal Expression: Nav1.8 is largely absent from the CNS
- Spinal Cord: Low-level expression in dorsal horn neurons
- Brain: Negligible expression
Nav1.8 is central to peripheral pain signaling:
flowchart LR
A["Noxious Stimulus"] --> B["Thermal/Mechanical/Chemical"]
B --> C["Nociceptor Terminal"]
C --> D["Nav1.8 Activation"]
D --> E["Depolarization"]
E --> F["Action Potential Initiation"]
F --> G["Central Synapse"]
G --> H["Pain Perception"]
D --> I["Sustained Firing"]
I --> J["Chronic Pain Signals"]
style H fill:#ffcdd2
style J fill:#ffcdd2
- Threshold Activation: Nav1.8 activates at depolarized potentials, requiring strong stimuli
- Amplification: Slow inactivation allows cumulative depolarization
- Repetitive Firing: Supports high-frequency action potential trains
- Signal Propagation: Ensures reliable action potential conduction
Nav1.8 displays remarkable temperature sensitivity:
- Heat Activation: Activates at temperatures >40°C
- Threshold Alignment: Matches heat pain threshold
- Thermosensation: Contributes to both acute and chronic thermal pain
Nav1.8 participates in neuroimmune cross-talk:
- Inflammatory Mediator Sensitization: Upregulated by prostaglandins, ATP
- Macrophage/Schwann Cell Expression: Expression in non-neuronal cells during injury
- Trophic Factor Regulation: Modulated by NGF and other growth factors
SCN10A mutations are a common cause of inherited small fiber neuropathy[@faber2019]:
- Pain Phenotype: Burning, stabbing, or electric shock-like pain
- Allodynia: Pain from normally non-painful stimuli
- Hypoalgesia: Reduced pain sensation in some variants
- Autonomic Symptoms: Sweating abnormalities, orthostatic intolerance
| Mutation Type |
Effect |
Phenotype |
| Gain-of-Function |
Increased channel activity |
Pain amplification |
| Loss-of-Function |
Reduced channel activity |
Reduced pain (Congenital insensitivity) |
| Missense |
Altered properties |
Variable |
flowchart TD
A["SCN10A Mutation"] --> B["Altered Nav1.8 Function"]
B --> C["Abnormal Nociceptor Activity"]
C --> D["Dysregulated Pain Signaling"]
D --> E["Small Fiber Degeneration"]
E --> F["Neuropathic Pain Symptoms"]
style F fill:#ffcdd2
SCN10A variants are associated with several cardiac conditions[@behrends2021]:
- Prevalence: ~20% of Brugada syndrome cases have SCN10A variants
- Mechanism: Reduced cardiac sodium current (INa)
- Interaction: Often co-occurs with SCN5A (Nav1.5) variants
- AV Block: Increased risk of heart block
- Bundle Branch Block: Delayed ventricular conduction
- Sudden Cardiac Death: Risk in severe cases
- GWAS Associations: Multiple SCN10A variants linked to AF risk
- Mechanism: Altered atrial electrophysiology
Common SCN10A variants influence pain susceptibility:
| Condition |
SCN10A Association |
Effect Size |
| Chronic Pain |
Risk variants |
Moderate |
| Post-surgical Pain |
Increased intensity |
Small-Medium |
| Fibromyalgia |
Nominal association |
Small |
| Migraine |
Possible association |
Limited |
- Diabetic Neuropathy: SCN10A variants modify risk and severity
- Chemotherapy-induced Neuropathy: Altered susceptibility
- Post-herpetic Neuralgia: Possible role in severity
¶ Drug Development Landscape
Nav1.8 is a prime target for pain therapeutics, but drug development has faced challenges[@mcgowan2022]:
graph LR
A["Nav1.8 Drug Targets"] --> B["Small Molecules"]
A --> C["Peptide Toxins"]
A --> D["ASOs"]
A --> E["mAbs"]
B --> B1["Clinical Trials"]
B1 --> B2["Failed - CNS effects"]
C --> C1["Phase I/II"]
D --> D1["Preclinical"]
E --> E1["Preclinical"]
style B2 fill:#ffcdd2
style C1 fill:#c8e6c9
| Drug |
Company |
Status |
Challenge |
| A-803467 |
Pfizer |
Preclinical |
Limited selectivity |
| VX-150 |
Vertex |
Phase II |
Failed - side effects |
| PF-04531083 |
Pfizer |
Phase II |
Terminated |
| RN-1734 |
Ricerca |
Preclinical |
Bioavailability |
¶ Clinical Trial Failures and Lessons
- CNS Side Effects: Early Nav1.8 blockers caused CNS adverse effects
- Peripheral Selectivity: Newer compounds aim for peripheral-only inhibition
- Species Differences: Rodent vs. human channel differences complicate translation
- Protoxin II (μ-TRTX Tx3-3): From tarantula venom, highly selective
- Clinical Trial: Phase I completed
- Advantage: High selectivity, no CNS penetration
- ASO Strategy: Knock down SCN10A expression
- Advantages: Long duration, target specificity
- Challenges: Delivery, cost
- AAV-Mediated: Targeted delivery to DRG neurons
- CRISPR: Potential for precision editing
- siRNA: Short-term knockdown
- Biomarkers: Pain relief correlates with Nav1.8 inhibition markers
- Genetic Testing: SCN10A genotyping for precision medicine
- Combination Therapy: Nav1.8 + Nav1.7 dual targeting
- Peripheral Selectivity: Critical for safety
¶ Research Directions and Knowledge Gaps
¶ Outstanding Questions
- Structure-Function: How do specific mutations alter channel properties?
- Cellular Regulation: What controls SCN10A expression after injury?
- Species Differences: Why do human and rodent channels differ?
- Cardiac Role: What is the exact contribution of Nav1.8 to cardiac conduction?
- Therapeutic Window: What level of inhibition is optimal?
- Cryo-EM Structures: High-resolution structures of Nav1.8
- Single-Cell Transcriptomics: DRG neuron subtypes expressing SCN10A
- iPSC Models: Patient-derived neurons for disease modeling
- Functional Genomics: CRISPR screens for modifiers
- SCN9A - Nav1.7, pain channel
- SCN11A - Nav1.9, pain channel
- SCN5A - Cardiac sodium channel
- SCN1B - Beta subunit
- Waxman SG, et al. Nav1.8 biology (2020)
- Faber CG, et al. SCN10A and small fiber neuropathy (2019)
- Behrends M, et al. SCN10A in cardiac arrhythmias (2021)
- McGowan J, et al. Nav1.8 drug development (2022)
- Dib-Hajj SD, et al. Sodium channels in pain (2019)
- Yang Y, et al. Nav1.8 in neuropathic pain (2018)
- Cummins TR, et al. Sodium channel gating (2007)
- Estacion M, et al. SCN10A mutations and pain (2009)
- Herreragranados I, et al. Nav1.8 and cardiac conduction (2016)
- Han C, et al. SCN10A and peripheral neuropathy (2017)
- Wu J, et al. Nav1.8 drug development (2020)
- Levesque M, et al. Nav1.8 in sensory neurons (2017)
Last updated: 2026-03-25